MA43037A - Polythérapie par inhibiteurs de bromodomaine et blocage de point de contrôle - Google Patents

Polythérapie par inhibiteurs de bromodomaine et blocage de point de contrôle

Info

Publication number
MA43037A
MA43037A MA043037A MA43037A MA43037A MA 43037 A MA43037 A MA 43037A MA 043037 A MA043037 A MA 043037A MA 43037 A MA43037 A MA 43037A MA 43037 A MA43037 A MA 43037A
Authority
MA
Morocco
Prior art keywords
polytherapy
bromodomain inhibitor
checkpoint blocking
checkpoint
blocking
Prior art date
Application number
MA043037A
Other languages
English (en)
Inventor
James E Bradner
Simon John Hogg
Ricky Wayne Johnston
Jake Shortt
Original Assignee
Dana Farber Cancer Inst Inc
Peter Maccallum Cancer Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana Farber Cancer Inst Inc, Peter Maccallum Cancer Inst filed Critical Dana Farber Cancer Inst Inc
Publication of MA43037A publication Critical patent/MA43037A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MA043037A 2015-10-02 2016-09-30 Polythérapie par inhibiteurs de bromodomaine et blocage de point de contrôle MA43037A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562236280P 2015-10-02 2015-10-02

Publications (1)

Publication Number Publication Date
MA43037A true MA43037A (fr) 2018-08-08

Family

ID=57137298

Family Applications (1)

Application Number Title Priority Date Filing Date
MA043037A MA43037A (fr) 2015-10-02 2016-09-30 Polythérapie par inhibiteurs de bromodomaine et blocage de point de contrôle

Country Status (16)

Country Link
US (1) US20190192532A1 (fr)
EP (1) EP3355922A2 (fr)
JP (1) JP2018530554A (fr)
KR (1) KR20180081507A (fr)
CN (1) CN108289957A (fr)
AR (1) AR107500A1 (fr)
AU (1) AU2016331190A1 (fr)
BR (1) BR112018006689A2 (fr)
CA (1) CA2999523A1 (fr)
CL (1) CL2018000853A1 (fr)
HK (1) HK1256269A1 (fr)
IL (1) IL258212A (fr)
MA (1) MA43037A (fr)
MX (1) MX2018003824A (fr)
PE (1) PE20181068A1 (fr)
WO (1) WO2017059319A2 (fr)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101510065B1 (ko) * 2005-06-08 2015-04-07 다나-파버 캔서 인스티튜트 인크. 예정 세포사 1(ｐｄ-1) 경로를 억제함으로써 지속 감염 및 암을 치료하기 위한 방법 및 조성물
US8986702B2 (en) 2008-05-16 2015-03-24 Taiga Biotechnologies, Inc. Antibodies and processes for preparing the same
DK2966084T3 (en) 2008-08-28 2018-08-06 Taiga Biotechnologies Inc MODULATORS OF MYC, PROCEDURES FOR USING SAME AND PROCEDURES FOR IDENTIFYING SUBSTANCES MODULATING MYC
MX384074B (es) 2010-05-14 2025-03-12 Dana Farber Cancer Inst Inc Composiciones y métodos para tratar neoplasias, enfermedades inflamatorias y otros trastornos.
MX373121B (es) 2010-05-14 2020-04-30 Dana Farber Cancer Inst Inc Composiciones y metodos para el tratamiento de leucemia.
AU2013292330B2 (en) 2012-07-20 2018-07-12 Htyr Acquisition Llc Enhanced reconstitution and autoreconstitution of the hematopoietic compartment
EP3066101B1 (fr) 2013-11-08 2020-07-29 Dana-Farber Cancer Institute, Inc. Polythérapie pour le traitement du cancer utilisant des inhibiteurs de protéine à bromodomaine et à domaine extra-terminal (bet)
KR20160130778A (ko) 2014-02-28 2016-11-14 텐샤 세러퓨틱스 인코포레이티드 고인슐린혈증과 관련된 질환의 치료
AU2015339511B2 (en) 2014-10-27 2020-05-14 Tensha Therapeutics, Inc. Bromodomain inhibitors
MX389710B (es) 2016-05-27 2025-03-20 Agenus Inc Anticuerpos anti proteina inmunoglobulina de linfocitos t y dominio de mucina 3 (tim-3) y métodos para usarlos.
CN113786476A (zh) 2016-12-02 2021-12-14 泰加生物工艺学公司 纳米颗粒调配物
IL315310A (en) 2017-12-26 2024-10-01 Kymera Therapeutics Inc Irak degraders and uses thereof
EP3737666A4 (fr) 2018-01-12 2022-01-05 Kymera Therapeutics, Inc. Agents de dégradation de protéines et utilisations associées
JP7169005B2 (ja) * 2018-01-16 2022-11-10 深▲チェン▼市塔吉瑞生物医薬有限公司 キナーゼ活性を阻害するためのジフェニルアミノピリミジン系化合物
EP3817822A4 (fr) 2018-07-06 2022-07-27 Kymera Therapeutics, Inc. Agents de dégradation de protéines et leurs utilisations
US12187686B2 (en) * 2018-09-07 2025-01-07 H. Lee Moffitt Cancer Center And Research Institute, Inc. BRD4-JAK2 inhibitors
TWI816881B (zh) * 2018-09-13 2023-10-01 大陸商恒翼生物醫藥（上海）股份有限公司 用於治療三陰性乳癌之組合療法
JP7623943B2 (ja) 2018-11-30 2025-01-29 カイメラ セラピューティクス， インコーポレイテッド Ｉｒａｋ分解剤およびそれらの使用
CN109666723B (zh) * 2019-01-22 2022-04-15 南通大学 一种基于pdl1/pdl2超增强子的免疫检测点抑制剂的应用
CN113874033A (zh) 2019-04-08 2021-12-31 泰加生物工艺学公司 用于冷冻保存免疫细胞的组合物和方法
JP2022532608A (ja) * 2019-05-14 2022-07-15 タイガ バイオテクノロジーズ，インク． Ｔ細胞疲弊を処置するための組成物および方法
BR112021026517A2 (pt) 2019-06-28 2022-05-10 Kymera Therapeutics Inc Degradadores de irak e usos dos mesmos
US20230093080A1 (en) * 2019-07-15 2023-03-23 Kymera Therapeutics, Inc. Protein degraders and uses thereof
WO2021011868A1 (fr) 2019-07-17 2021-01-21 Kymera Therapeutics, Inc. Agents de dégradation d'irak et leurs utilisations
TWI867086B (zh) * 2019-11-05 2024-12-21 加拿大商瑞斯弗洛吉克斯公司 以rvx-208及sglt2抑制劑治療及/或預防主要不良心血管事件(mace)的方法
KR102420262B1 (ko) * 2019-11-26 2022-07-13 주식회사 베노바이오 신규한 퀘르세틴 리독스 유도체 및 bet 억제제로서의 용도
EP4072591A4 (fr) 2019-12-10 2024-06-05 Kymera Therapeutics, Inc. Agents de dégradation d'irak et leurs utilisations
JP2023509366A (ja) 2019-12-17 2023-03-08 カイメラ セラピューティクス， インコーポレイテッド Ｉｒａｋ分解剤およびそれらの使用
WO2021175432A1 (fr) 2020-03-04 2021-09-10 Boehringer Ingelheim International Gmbh Procédé d'administration d'un agent anticancéreux
TW202210483A (zh) 2020-06-03 2022-03-16 美商凱麥拉醫療公司 Irak降解劑之結晶型
US11691971B2 (en) 2020-06-19 2023-07-04 Incyte Corporation Naphthyridinone compounds as JAK2 V617F inhibitors
WO2021257863A1 (fr) 2020-06-19 2021-12-23 Incyte Corporation Composés de pyrrolotriazine utilisés en tant qu'inhibiteurs de v617f de jak2
WO2022006456A1 (fr) 2020-07-02 2022-01-06 Incyte Corporation Composés de pyridone tricyclique en tant qu'inhibiteurs de v617f de jak2
BR112023000047A2 (pt) 2020-07-02 2023-03-14 Incyte Corp Compostos de ureia tricíclicos como inibidores da v617f da jak2
US11661422B2 (en) 2020-08-27 2023-05-30 Incyte Corporation Tricyclic urea compounds as JAK2 V617F inhibitors
WO2022140231A1 (fr) 2020-12-21 2022-06-30 Incyte Corporation Composés de déazaguanine utilisés en tant qu'inhibiteurs de v617f de jak2
WO2022147465A1 (fr) 2020-12-30 2022-07-07 Kymera Therapeutics, Inc. Agents de dégradation d'irak et leurs utilisations
TW202245788A (zh) 2021-02-15 2022-12-01 美商凱麥拉醫療公司 Irak4降解劑及其用途
AU2022227673A1 (en) * 2021-02-25 2023-08-17 Impact Biomedicines, Inc. Use of a bet inhibitor alone or in combination with fedratinib or ruxolitinib for treating a hematological malignancy such as myelofibrosis
AR125273A1 (es) 2021-02-25 2023-07-05 Incyte Corp Lactamas espirocíclicas como inhibidores de jak2 v617f
EP4422635A4 (fr) 2021-10-29 2025-11-26 Kymera Therapeutics Inc Agents de dégradation d'irak4 et leur synthèse
IL314437A (en) 2022-01-31 2024-09-01 Kymera Therapeutics Inc IRAK joints and their uses
KR20240163688A (ko) 2022-03-17 2024-11-19 인사이트 코포레이션 Jak2 v617f 억제제로서의 삼환계 우레아 화합물

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2496580B1 (fr) * 2009-11-05 2013-12-11 GlaxoSmithKline LLC Inhibiteur de bromodomaine de benzodiazépine
US9301962B2 (en) * 2010-05-14 2016-04-05 Baylor College Of Medicine Male contraceptive compositions and methods of use
MX384074B (es) * 2010-05-14 2025-03-12 Dana Farber Cancer Inst Inc Composiciones y métodos para tratar neoplasias, enfermedades inflamatorias y otros trastornos.
JP5715241B2 (ja) * 2010-05-14 2015-05-07 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド 新生物、炎症性疾患、およびその他の障害を治療するための組成物および方法
US9249161B2 (en) * 2010-12-02 2016-02-02 Constellation Pharmaceuticals, Inc. Bromodomain inhibitors and uses thereof
JP2016513117A (ja) * 2013-02-22 2016-05-12 バイエル ファーマ アクチエンゲゼルシャフト 過剰増殖性疾患を治療するためのｂｅｔタンパク質阻害剤としてのピロロ−およびピラゾロ−トリアゾロジアゼピン類
HK1212345A1 (en) * 2013-02-22 2016-06-10 Bayer Pharma Aktiengesellschaft 4-substituted pyrrolo- and pyrazolo-diazepines
CN105050595A (zh) * 2013-03-15 2015-11-11 基因泰克公司 通过抑制含布罗莫结构域蛋白brd7和brd9治疗th2介导的疾病
WO2015018522A1 (fr) * 2013-08-06 2015-02-12 Oncoethix Sa Inhibiteur de bromodomaine bet présentant une synergie avec plusieurs agents anti-cancéreux dans des modèles cliniques de lymphome diffus de cellule b de grande taille (dlbcl)
KR20160037201A (ko) * 2013-08-06 2016-04-05 온코에틱스 게엠베하 Bet-브로모도메인 억제제를 사용한 미만성 거대 b-세포 림프종 (dlbcl)의 치료 방법
KR20160060765A (ko) * 2013-10-11 2016-05-30 제넨테크, 인크. 암 면역요법을 위한 cbp/ep300 브로모도메인 억제제의 용도
HUE054183T2 (hu) * 2013-12-24 2021-08-30 Bristol Myers Squibb Co Triciklusos vegyület rákellenes szerekként

Also Published As

Publication number Publication date
WO2017059319A2 (fr) 2017-04-06
CN108289957A (zh) 2018-07-17
BR112018006689A2 (pt) 2018-10-09
CL2018000853A1 (es) 2018-08-31
AR107500A1 (es) 2018-05-09
PE20181068A1 (es) 2018-07-04
AU2016331190A1 (en) 2018-04-12
MX2018003824A (es) 2019-04-01
IL258212A (en) 2018-05-31
WO2017059319A3 (fr) 2017-10-12
CA2999523A1 (fr) 2017-04-06
US20190192532A1 (en) 2019-06-27
EP3355922A2 (fr) 2018-08-08
JP2018530554A (ja) 2018-10-18
KR20180081507A (ko) 2018-07-16
HK1256269A1 (zh) 2019-09-20

Similar Documents

Publication Publication Date Title
IL284748A (en) Anti-cyberbullying systems and methods
IL259766B (en) Relocalization systems and methods
IL285053A (en) Hsd17b13 variants and uses thereof
MA52814A (fr) Inhibiteurs de bromodomaine
EP3283077A4 (fr) Inhibiteurs de bromodomaine
IL264063B (en) Combination comprising ep4 antagonist and immune checkpoint inhibitor
EP3626699A4 (fr) Inhibiteur de ssao
IL280863A (en) Autotaxin inhibitors and uses thereof
EP3360320C0 (fr) Systèmes et procédés de projection
EP3576036A4 (fr) Dispositif et procédé d'exécution de service
PT3606519T (pt) Compostos de inibidor de ask1 e utilizações dos mesmos
IL259479B (en) Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor
KR102068915B9 (ko) 조직 인자 경로 억제제 항체 및 그의 용도
EP3532059A4 (fr) Polythérapie par inhibiteur de protéine à bromodomaine et domaine extra-terminal
BR112017022691A2 (pt) inibidor de bromodomínio.
EP3370773A4 (fr) Polythérapie constituées d'immunotoxines et d'un inhibiteur de point de contrôle
MA49905A (fr) Polyesteramines et polyesterquats
EP3526210A4 (fr) Inhibiteurs de bromodomaine
EP3683214A4 (fr) Inhibiteur de brd4
EP3983013A4 (fr) Molécules bispécifiques de blocage de point de contrôle immunitaire
EP3526197A4 (fr) Inhibiteurs de bromodomaine
EP3854224A4 (fr) Inhibiteur de point de contrôle immunitaire
EP3729136A4 (fr) Autodirecteur guidé par un événement
DK3727533T3 (da) Blokeringsanordning
EP3528810A4 (fr) Inhibiteur de bromodomaines